Volume | 2 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CERo Therapeutics Holdings Inc | CERO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.7032 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
2 | 2 | - | 0.66 - 12.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
06:48:26 | 1 | $ 0.7032 | USD |
CERo Therapeutics Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 10.59M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
CERo Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CERO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.99 | 1.02 | 0.66 | 0.7456022 | 725,012 | -0.2868 | -28.97% |
1 Month | 1.14 | 1.17 | 0.66 | 0.784749 | 227,620 | -0.4368 | -38.32% |
3 Months | 2.06 | 3.76 | 0.66 | 2.58 | 683,204 | -1.36 | -65.86% |
6 Months | 5.25 | 12.38 | 0.66 | 2.93 | 890,092 | -4.55 | -86.61% |
1 Year | 5.25 | 12.38 | 0.66 | 2.93 | 890,092 | -4.55 | -86.61% |
3 Years | 5.25 | 12.38 | 0.66 | 2.93 | 890,092 | -4.55 | -86.61% |
5 Years | 5.25 | 12.38 | 0.66 | 2.93 | 890,092 | -4.55 | -86.61% |
CERo Therapeutics Description
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company¿s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body¿s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies. |